Cuba Begins China Registration of Diabetic Ulcer Drug
08 May 2009
ChinaBio Today -- Cuban officials have begun the registration process in China for Heberprot-B, an innovative treatment for chronic diabetic ulcers in the extremities. Developed by Havana’s Center for Genetic Engineering and Biotechnology (CIGB), Heberprot-B is said to reduce the need for amputation by 50%. The drug underwent Cuban clinical trials in more than 300 patients, and has been approved for use there since 2006. More details...
Organizations
-Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.